Female Reproductive System Clear Cell Adenocarcinoma

Female Reproductive System Clear Cell Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 27
Recruiting: 11
Ph III recruiting: 3
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–16 of 16 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05920798	Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer(FRAPPE)	active not recruiting	Phase 1 / Phase 2	38	Mayo ClinicOTHER	1	Sep 21, 2026	clinicaltrials
NCT02101775	Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	active not recruiting	Phase 2	124	National Cancer Institute (NCI)NIH	3